



Northeast Ohio

MEDICAL UNIVERSITY

**Keynote Speaker 2017 Ohio Physiological Society 32nd annual meeting
NEOMED – NEW Center
October 27, 2017**



Kenneth Walsh, Ph.D. is the Aram V. Chobanian Distinguished Professor of Medicine and the Director of the Whitaker Cardiovascular Institute in the Department of Medicine at Boston University School of Medicine. Dr. Walsh, who hails from Ohio, earned his bachelor's degree at Bowling Green State University and his PhD in Biochemistry from the University of California, Berkeley. His research examines molecular events that drive cardiovascular cell growth, differentiation and apoptosis, and his laboratory performed seminal studies documenting the importance of Akt/PKB signaling in the function and growth of cardiovascular tissues. Over the past decade his laboratory has investigated mechanisms of inter-tissue communication and how these systems contribute to physiological versus pathological tissue growth in the cardiovascular system, particularly as it relates to obesity and systemic metabolic dysfunction. Dr. Walsh has published more than 350 scientific articles and he has been the recipient of multiple research grants from the National Institutes of Health, including a MERIT Award. Dr. Walsh has served as a charter member of the CCHF study section for NIH. He was an Associate Editor for the journal *Circulation* for 12 years and currently serves on numerous editorial boards including *Science Signaling*, *Arteriosclerosis, Thrombosis and Vascular Biology*, *Circulation Research* and others. Dr. Walsh is the recipient of the prestigious Irvine F. Page Award from the Council on Arteriosclerosis and was previously an Established Investigator of the American Heart Association. In 2011, he was designated "Distinguished Scientist" by the AHA for his contributions to cardiovascular research. His current research is focused on delineating how somatic mutations in hematopoietic cells contribute to the cardiometabolic disease process. This research has elucidated a common mechanistic basis between hematological cancer and atherosclerosis, and suggests that somatic mutations in leukocytes represent a new causal risk factor for cardiovascular disease.

Detailed information regarding abstracts, registration and housing will be posted in August on the Ohio Physiological Society website: ohio-physiological-society.org.

For more information, contact Dr. J. Gary Meszaros at jgmeszar@neomed.edu or 330.325.6432, Karen Greene at kjg@neomed.edu or 330.325.6429 or Ileen Ciccozzi at iciccozzi@neomed.edu or 330.325.6436.